230 related articles for article (PubMed ID: 17993848)
1. Correction factors for more accurate estimates of exposure rates near radioactive patients: experimental, point, and line source models.
Willegaignon J; Guimarães MI; Stabin MG; Sapienza MT; Malvestiti LF; Marone MM; Sordi GM
Health Phys; 2007 Dec; 93(6):678-88. PubMed ID: 17993848
[TBL] [Abstract][Full Text] [Related]
2. A new proposal for monitoring patients in nuclear medicine.
Willegaignon J; Guimarães MI; Sapienza MT; Stabin MG; Malvestiti LF; Marone M; Sordi GM
Health Phys; 2006 Dec; 91(6):624-9. PubMed ID: 17099406
[TBL] [Abstract][Full Text] [Related]
3. Hospital discharge of patients with thyroid carcinoma treated with 131I.
Venencia CD; Germanier AG; Bustos SR; Giovannini AA; Wyse EP
J Nucl Med; 2002 Jan; 43(1):61-5. PubMed ID: 11801704
[TBL] [Abstract][Full Text] [Related]
4. [Radiation exposure in the environment of patients after application of radiopharmaceuticals. Part 2: Therapeutic procedures].
Sudbrock F; Boldt F; Kobe C; Hammes J; Eschner W; Schicha H
Nuklearmedizin; 2009; 48(1):17-25. PubMed ID: 19212607
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the potential absorbed doses from patients based on whole-body 131I clearance in thyroid cancer therapy.
Willegaignon J; Stabin MG; Guimarães MI; Malvestiti LF; Sapienza MT; Maroni M; Sordi GM
Health Phys; 2006 Aug; 91(2):123-7. PubMed ID: 16832193
[TBL] [Abstract][Full Text] [Related]
6. Calculating the absorbed dose from radioactive patients: the line-source versus point-source model.
Siegel JA; Marcus CS; Sparks RB
J Nucl Med; 2002 Sep; 43(9):1241-4. PubMed ID: 12215565
[TBL] [Abstract][Full Text] [Related]
7. Radiation exposure after permanent prostate brachytherapy.
Cattani F; Vavassori A; Polo A; Rondi E; Cambria R; Orecchia R; Tosi G
Radiother Oncol; 2006 Apr; 79(1):65-9. PubMed ID: 16564593
[TBL] [Abstract][Full Text] [Related]
8. Comparison of measured and calculated dose rates near nuclear medicine patients.
Yi Y; Stabin MG; McKaskle MH; Shone MD; Johnson AB
Health Phys; 2013 Aug; 105(2):187-91. PubMed ID: 23799503
[TBL] [Abstract][Full Text] [Related]
9. Patient parameters and other radiation safety issues in 131I therapy for thyroid cancer treatment.
Al-Haj AN; Lagarde CS; Lobriguito AM
Health Phys; 2007 Dec; 93(6):656-66. PubMed ID: 17993846
[TBL] [Abstract][Full Text] [Related]
10. Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer.
Tuttle RM; Leboeuf R; Robbins RJ; Qualey R; Pentlow K; Larson SM; Chan CY
J Nucl Med; 2006 Oct; 47(10):1587-91. PubMed ID: 17015892
[TBL] [Abstract][Full Text] [Related]
11. The effects of a custom-made lead collar on dose rates of patients treated with 131I.
Stapel AG; van der Zant FM; Gommans GM; Boer RO; Reigman HI
Health Phys; 2009 May; 96(5 Suppl 2):S64-8. PubMed ID: 19359844
[TBL] [Abstract][Full Text] [Related]
12. Liquid discharges from patients undergoing 131I treatments.
Barquero R; Basurto F; Nuñez C; Esteban R
J Environ Radioact; 2008 Oct; 99(10):1530-4. PubMed ID: 18243440
[TBL] [Abstract][Full Text] [Related]
13. Improved prediction of therapeutic absorbed doses of radioiodine in the treatment of thyroid carcinoma.
Hermanská J; Kárný M; Zimák J; Jirsa L; Sámal M; Vlcek P
J Nucl Med; 2001 Jul; 42(7):1084-90. PubMed ID: 11438632
[TBL] [Abstract][Full Text] [Related]
14. Comparing dose rates near a radioactive patient evaluated using various source models: point, line, cylinder, and anthropomorphic phantoms.
Liu YC; Lee KW; Sheu RJ
Health Phys; 2015 Jul; 109(1):69-77. PubMed ID: 26011499
[TBL] [Abstract][Full Text] [Related]
15. [Environmental radiation dose monitor after 125I radioactive seed implantation].
Zhuo SQ; Chen L; Zhang FJ; Zhao M; Zhang L; Liu J; Li K; Wu PH; Zheng QS; Wang Y
Ai Zheng; 2007 Jun; 26(6):666-8. PubMed ID: 17562278
[TBL] [Abstract][Full Text] [Related]
16. External dose rates in radioiodine treatment of benign goitre: estimation versus direct measurement.
Jørgensen HB; Høilund-Carlsen PF; Nielsen VE
Scand J Clin Lab Invest; 2006; 66(6):509-16. PubMed ID: 17000558
[TBL] [Abstract][Full Text] [Related]
17. Radiation dose to family members of hyperthyroidism and thyroid cancer patients treated with 131I.
Pant GS; Sharma SK; Bal CS; Kumar R; Rath GK
Radiat Prot Dosimetry; 2006; 118(1):22-7. PubMed ID: 16105892
[TBL] [Abstract][Full Text] [Related]
18. [Environmental radiation exposure of a thyroid cancer patient resulting from adjuvant iodine radiotherapy].
Chaś J; Kowalczyk A; Siekierzyński M; Dziuk E; Janiak MK
Wiad Lek; 2001; 54 Suppl 1():312-20. PubMed ID: 12182042
[TBL] [Abstract][Full Text] [Related]
19. Radiation safety considerations for post-iodine-131 thyroid cancer therapy.
Culver CM; Dworkin HJ
J Nucl Med; 1992 Jul; 33(7):1402-5. PubMed ID: 1613585
[TBL] [Abstract][Full Text] [Related]
20. [Dosimetric measurements and early complications in patients with differentiated thyroid carcinomas treated with radioactive iodine].
Malesević M; Stefanović L; Adzić O; Mihoci Z; Elez D
Med Pregl; 1992; 45(11-12):427-31. PubMed ID: 1344442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
